Currently, the standard therapy for HR+/HER2-breast cancer patients is treated with aromatase inhibitors (e.g., anastrazole, letrozole, or exemestane) alone or in combination with cyclin-dependent kinase 4/6 inhibitors (e.g., ribociclib, palbociclib, or abemaciclib) [5]. This evidence concerns the gene ERBB2 and breast carcinoma.